Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors
Open-label trial shows no significant change in fecal calprotectin in psoriasis patients switching to brodalumab, implying limited association with inflammatory bowel disease.
Key Points
This research aimed to assess the impact of switching psoriasis patients from TNF-α inhibitors to brodalumab on their calprotectin levels.
Open-label, randomized, parallel-group cross-over study
Included 20 patients with moderate-to-severe psoriasis
Measured serum and fecal calprotectin levels at baseline and after 12 weeks of brodalumab treatment
Conducted statistical analysis on calprotectin levels and clinical factors
Serum and fecal calprotectin levels were elevated before treatment, especially in fecal samples
No significant changes in calprotectin levels after switching to brodalumab
No correlations found between calprotectin levels and PASI, BMI, age, sex, NSAID or PPI use, or disease duration